Answers are grounded in this paper and cite their sources.
Treatment patterns were evaluated in US patients prescribed the osteoporosis therapies abaloparatide, teriparatide, and romosozumab. Despite current guidelines, many patients did not take these medications for the recommended time, nor receive recommended follow-up osteoporosis therapy after finishing the medication. Further research is needed to develop strategies to overcome these gaps in care. PURPOSE: The goal of osteoporosis therapy is to reduce fracture risk. The persistence and sequence of therapy affect clinical outcomes. This study evaluated real-world patterns of treatment persistence and sequence in US patients prescribed osteoanabolic therapies. METHODS: This retrospective cohort study used administrative claims data from ICON's Symphony Health Integrated Dataverse database. Men and women ≥50 years of age prescribed the osteoanabolic therapies abaloparatide (ABL), teriparatide (TPTD), or romosozumab (ROMO) were included. The index date was the date of the first osteoanabolic prescription claim; patients were required to have medical and pharmacy records for at least 5 years before and at least 1 year after discontinuation of the index osteoanabolic therapy. RESULTS: This study included 43,429 men and women (16,592 [38%] ABL, 19,491 [45%] TPTD, and 7346 [17%] ROMO). The most common osteoanabolic prescriber specialties were endocrinology, rheumatology, and family medicine. Despite differences in labeled duration of use, persistence rates were low, with only 35% of ABL and 33% of TPTD patients receiving therapy for more than 12 months, while 56% of ROMO patients received therapy for more than 9 months. In the 12 months after discontinuation of osteoanabolic therapy, 28% (ABL), 26% (TPTD), and 57% (ROMO) of patients received subsequent antiresorptive therapy. The most common therapies before and after an osteoanabolic were oral bisphosphonates and denosumab. CONCLUSION: Despite existing clinical guidelines, this analysis found major gaps in osteoporosis treatment among US adults. Further research is required to develop strategies to overcome the obstacles in applying standard of care practices.
No takes yet. Share an insight, caveat, or question.
Lewiecki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: